GeneDx Hldgs Q2 2024 Adj. EPS $(0.10) Beats $(0.30) Estimate, Sales $70.514M Beat $59.311M Estimate
Portfolio Pulse from Benzinga Newsdesk
GeneDx Holdings (NASDAQ:WGS) reported better-than-expected Q2 2024 results with an adjusted EPS of $(0.10) beating the $(0.30) estimate and sales of $70.514 million surpassing the $59.311 million estimate. This represents a 44.77% increase in sales compared to the same period last year.
July 30, 2024 | 8:59 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
GeneDx Holdings reported Q2 2024 adjusted EPS of $(0.10), beating the $(0.30) estimate by 66.67%. Sales were $70.514 million, surpassing the $59.311 million estimate by 18.89%, and representing a 44.77% increase YoY.
The significant beat on both EPS and sales estimates, along with a substantial year-over-year sales increase, is likely to positively impact the stock price of GeneDx Holdings in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100